Amgen’s experimental bone drug reduced the risk of spinal fractures in women with osteoporosis by 68 percent in a pivotal clinical trial.

The company is halting some pricing practices that critics say were contributing to overuse of its flagship anemia drug Aranesp at a time of mounting concerns about the product’s safety.

Amgen is halting some pricing practices that critics say were contributing to overuse of its flagship anemia drug Aranesp at a time of mounting concerns about the product’s safety.

The Food and Drug Administration has ordered Amgen to change the labels for its flagship anemia drugs in a way that could further restrict their use in treating patients with cancer.

The move, which the F.D.A. is expected to announce on Wednesday, represents the first time the agency has ordered changes in a drug’s prescribing information.

Amgen reported a far better than expected quarterly profit as sales of its anemia drug Aranesp rebounded from the preceding quarter.

Amgen reported a far better-than-expected quarterly profit as sales of its anemia drugs, hurt by safety concerns and reimbursement restrictions, declined less than expected, and the company raised its 2008 forecast.